Latest News
European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma
22 April 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that the European Commission has granted conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for patients aged si...
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
22 April 2026 - Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) announced on Wednesday that it has appointed US-based research and investor engagement firm Water Tower Research LLC to enhance its understanding of the US market, refine...
Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases
22 April 2026 - Ondine Biomedical Inc (LON: OBI), a provider of photodisinfection-based therapies, announced on Wednesday that it has secured acceptance of two abstracts for poster presentation at the World Congress on Infectious Diseases, taking pla...
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
22 April 2026 - Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) revealed on Wednesday that it has completed key regulatory and operational milestones to support the scaling of its kidneyintelX.dkd diagnostic platform, ...
FDA extends review timeline for Sanofi's Sarclisa subcutaneous formulation in multiple myeloma
22 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has extended by up to three months the target action date for its review of the Biologics Li...